Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Summit Therapeutics Inc.

    NASDAQ: SMMT · Real-Time Price · USD
    23.84
    0.75 (3.25%)
    At close: May 16, 2025, 3:59 PM
    23.55
    -1.24%
    Pre-market: May 19, 2025, 04:11 AM EDT
    3.25%
    Bid 23.17
    Market Cap 17.59B
    Revenue (ttm) n/a
    Net Income (ttm) -240.75M
    EPS (ttm) -0.34
    PE Ratio (ttm) -70.13
    Forward PE -47.04
    Analyst Buy
    Ask 23.88
    Volume 1,341,660
    Avg. Volume (20D) 4,065,237
    Open 23.42
    Previous Close 23.09
    Day's Range 23.05 - 23.94
    52-Week Range 2.10 - 36.91
    Beta -0.95

    About SMMT

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SMMT
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SMMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 weeks ago
    -36.05%
    Summit Therapeutics shares are trading lower. The ... Unlock content with Pro Subscription
    3 weeks ago
    +21.5%
    Summit Therapeutics shares are trading higher after the company provided updates on its Phase 3 trial of Ivonescimab and announced it met its primary endpoint.
    news image

    1 day ago · fool.com

    Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money

    Everyone knows that it takes money to make money. However, you don't need much money to begin making money.

    news image

    3 days ago · businesswire.com

    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of...

    news image

    1 week ago · zacks.com

    Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know

    The consensus price target hints at a 33.4% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

    news image

    2 weeks ago · zacks.com

    Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil

    SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.

    news image

    2 weeks ago · fool.com

    This Soaring Stock Just Delivered More Good News. Time to Buy?

    It's hard to find a biotech company that has performed better than Summit Therapeutics (SMMT 2.86%) in the past year. The stock is up by a whopping 512%, and it's no secret why.

    news image

    2 weeks ago · businesswire.com

    Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

    MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for ...

    news image

    3 weeks ago · benzinga.com

    Why Is Summit Therapeutics Stock Trading Higher On Monday?

    Summit Therapeutics Inc.  SMMT on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indicati...

    news image

    3 weeks ago · fool.com

    Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

    Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTec...

    news image

    3 weeks ago · benzinga.com

    What's Going On With Summit Therapeutics Stock On Friday?

    Summit Therapeutics Inc SMMT stock is trading lower on Friday.

    news image

    3 weeks ago · businesswire.com

    Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

    MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was app...

    Add to Watchlist